Targeted Scan Detects Hidden Multiple Myeloma Missed by Standard Imaging

Advanced imaging tool improves detection of residual multiple myeloma disease

A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy.

Targeted scan detects hidden multiple myeloma missed by standard imaging

A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy. The phase 2 clinical trial was led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

Targeted scan detects hidden multiple myeloma

First-in-human immunoPET study found active disease in patients whose standard scans and blood tests show no signs of cancer